Cyclic peptides for treatment of cachexia

Details Cyclic peptides for treatment of cachexia Cyclic peptides for treatment of cachexia

2005-07-05

2008-03-18

Kam, Chih-Min (Department: 1656)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Melanotropin or eledoisin; related peptides

C530S317000, C530S321000, C530S300000, C530S328000, C530S329000, C514S009100, C514S011400, C514S012200, C514S015800, C514S016700, C514S018700, C424S009100, C436S811000

Reexamination Certificate

active

07345144

ABSTRACT:
A highly selective melanocortin-4 receptor antagonist cyclic hexapeptide of the formulawhere R1, R2, R3a, R3b, R4, R5, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.

REFERENCES:
patent: 4938763 (1990-07-01), Dunn et al.
patent: 5693608 (1997-12-01), Bechgaard et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5908825 (1999-06-01), Fasano et al.
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6100048 (2000-08-01), Cone et al.
patent: 6284729 (2001-09-01), Bernfield et al.
patent: 6432438 (2002-08-01), Shukla
patent: 6476187 (2002-11-01), Cone et al.
patent: 6613874 (2003-09-01), Mazur et al.
patent: 6673767 (2004-01-01), Brodbeck et al.
patent: 6693165 (2004-02-01), Bednarek
patent: 6699873 (2004-03-01), Maguire et al.
patent: 6716810 (2004-04-01), Brennan
patent: 2002/0016291 (2002-02-01), Bednarek
patent: 2003/0032791 (2003-02-01), Alan et al.
patent: 2003/0105024 (2003-06-01), Cone et al.
patent: 2003/0113263 (2003-06-01), Marks et al.
patent: WO 03/006620 (2003-01-01), None
Sawyer et al., Proc. Natl. Acad. Sci. USA 79, 1751-1755.
Huszar D., Lynch C. A., Fairchild-Huntress V., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131-141 (1997).
Roubenoff R. The pathophysiology of wasting in the elderly. J. Nutr. 129(1S Suppl.):256S-259S (1999).
Fan W., Boston B. A., Kesterson R.A ., Hruby V. J., Cone R. D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385:165-168 (1997).
Rossi M., Kim M. S., Morgan D. G., et al. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 139:4428-31 (1998).
Wisse B. E., Frayo R. S., Schwartz M. W., Cummings D. E. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142:3292-3301 (2001).
Marks D. L., Ling N., Cone R. D. Role of the central melanocortin system in cachexia. Cancer Research 61:1432-1438 (2001).
Synthetic Peptides: A User's Guide, G. A. Grant, editor, W.H. Freeman & Co., New York (1992) the teachings of which are incorporated herein by reference, including the text and table set forth at pp. 11 through 24.
Hruby V. J., Al obeidi F., Kazmierski W., Biochem. J. 268:249-262 (1990).
Toniolo C., Int. J. Peptide Protein Res. 35:287-300 (1990).
Galande A. K., Spatola A. F. Lett. Pept. Sci. 8:247 (2002).
Schioth H. B. et al. Peptides 18:1009-1013 (1997).
Merrifield R.B., Solid phase synthesis (Nobel lecture). Angew Chem 24:799-810 (1985).
Catania A. et al., Trends Endocrinol. Metab. 11:304-308 (2000).
Gantz I. and Fong T. M., Am. J. Physiol. Endocrinol. Metab. 284:E468-E474 (2003).
Catania A., Gatti S., Colombo G., Lipton J. M., Pharmacol. Rev. 56:1-29 (2004).

Affiliated with

Also associated with

Rating

Cyclic peptides for treatment of cachexia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptides for treatment of cachexia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptides for treatment of cachexia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3965266